For the 33 prioritisation (October 2017), 9 drugs were filtered out of 401 identified and were sent to prioritisation. Of these, 5 drugs were ranked as 'highly relevant' by the expert panel, 4 as 'relevant' and none as 'not relevant'. For 'highly relevant' drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.